Maker of Wegovy and Ozempic has 45,000 patients in clinical trials as it seeks to stave off threats from Eli Lilly and Roche
Swiss drugmaker unveils promising data for obesity drug
GSK’s Shingrix is latest drug to show potential for targeting previously untreatable brain disorders
Pharma groups could see almost threefold drop in demand due to US health official decision, says Airfinity
Pharma group seeks to catch up with rivals Eli Lilly and Novo Nordisk in sector projected to be worth $130bn a year
New compound increases strength of antidote for fentanyl and other lethal drugs
New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Federal health officials step up efforts to boost jab stockpiles in response to widening outbreak
Danish pharma group plans 1.4mn sq ft manufacturing plant in North Carolina to help meet surging demand
Oral formulation offers prospect of cheaper and more convenient access to drug, research suggests
Vutrisiran injection cut risk of death and adverse cardiovascular events by at least 28%, company says
As incidence rises, breakthroughs in oncology show the value of research funding
Both OZEM and THNR offer very concentrated bets on a fast-moving market
US decision hands biotech group its first regulatory blessing since its blockbuster Covid-19 jab
US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness
US drugmaker races to scale up ingredient production to meet demand for Mounjaro and Zepbound jabs
As Covid revenues slump, technology developed to fight the pandemic is having some success combating this disease
Weekly injection delivered 18.8% weight loss over 24 weeks
Study opens up potential to tackle a condition with few available treatment options
Trial participants also had cardiovascular benefits regardless of weight
Food and Drug Administration poised to call for outside assessment of Lykos PTSD therapy in test for psychedelics sector
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
